Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study - Scorecard - MDSpire

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

  • By

  • Hamza Khan

  • Muhammad Saqib Khan

  • Sheraz Khan

  • Fang Liu

  • Quan Feng

  • Irfan Ahmad

  • Ge Tan

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Assessing the Effectiveness of Rimegepant for Preventing Chronic and Episodic Migraine: A Three-Month Retrospective Cohort Analysis

At a Glance

CategoryDetail
ConditionMigraine (Chronic and Episodic)
Key MechanismsCalcitonin gene-related peptide (CGRP) receptor antagonist
Target PopulationAdults aged 18–65 years with chronic or episodic migraine
Care SettingReal-world clinical setting

Key Highlights

  • Rimegepant 75 mg every other day led to significant reductions in monthly headache days and monthly migraine days.
  • Improvements observed in HIT-6, MIDAS, and MSQ scores after 3 months.
  • Both chronic and episodic migraine patients showed significant improvements across all outcomes.

Guideline-Based Recommendations

Diagnosis

  • Chronic migraine: 15 or more headache days per month with at least 8 days meeting migraine criteria.

Management

  • Rimegepant is recommended for preventive treatment of episodic migraine.

Monitoring & Follow-up

  • Monitor changes in monthly headache days and migraine days, as well as patient-reported outcomes.

Risks

  • Limited specific data for chronic migraine prevention; off-label use in this population.

Patient & Prescribing Data

40 adults (mean age 41.12 years; 80% women) with chronic or episodic migraine.

Rimegepant associated with meaningful reductions in migraine frequency and headache-related disability.

Clinical Best Practices

  • Consider rimegepant for patients with inadequate response to traditional preventive therapies.
  • Evaluate patient-reported outcomes regularly to assess treatment efficacy.

Related Resources & Content

Original Source(s)

Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

  • by Hamza Khan, Muhammad Saqib Khan, Sheraz Khan, Fang Liu, Quan Feng, Irfan Ahmad, Ge Tan

  • June 4, 2026

Related Content

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.

IHS, ACP Differ on Migraine Tx

Experts highlight differences between IHS and ACP recommendations as newer therapies reshape acute and preventive migraine care

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan